MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).
Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine.MTL-501 is a saRNA liver cancer therapeutic that activates the CEBPA gene. Intravenous injection of MTL-501 in a liver cancer rat model reduced tumour burden by 80% whilst increasing significantly serum albumin. In vitro work has indicated the dramatic potential of CEBPA saRNA as a universal anti-cancer therapeutic in non-small cell lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma. MTL-301 is a Type 1 diabetes therapeutic. In vitro work demonstrated glucose responsive insulin secretion by both CD34+ adult stem cells and HepG2 cells.